D. E. Shaw & Co. Inc. decreased its holdings in HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) by 55.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 41,543 shares of the company's stock after selling 51,734 shares during the period. D. E. Shaw & Co. Inc.'s holdings in HUTCHMED were worth $599,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Barclays PLC increased its stake in shares of HUTCHMED by 1,483.6% during the fourth quarter. Barclays PLC now owns 2,407 shares of the company's stock worth $35,000 after purchasing an additional 2,255 shares during the period. Blue Trust Inc. grew its position in HUTCHMED by 99.9% during the fourth quarter. Blue Trust Inc. now owns 7,068 shares of the company's stock worth $102,000 after buying an additional 3,532 shares in the last quarter. Summit Trail Advisors LLC raised its holdings in HUTCHMED by 14.4% in the 4th quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company's stock valued at $189,000 after acquiring an additional 1,647 shares in the last quarter. OLD Mission Capital LLC bought a new stake in shares of HUTCHMED during the 4th quarter valued at $230,000. Finally, Marshall Wace LLP bought a new position in shares of HUTCHMED in the fourth quarter worth $261,000. 8.82% of the stock is owned by institutional investors.
HUTCHMED Trading Up 0.1%
Shares of HCM traded up $0.01 during midday trading on Friday, hitting $13.87. The company's stock had a trading volume of 26,729 shares, compared to its average volume of 89,427. The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07. HUTCHMED has a one year low of $11.51 and a one year high of $21.50. The company's fifty day simple moving average is $14.10 and its two-hundred day simple moving average is $14.89.
Analyst Upgrades and Downgrades
Several research firms recently weighed in on HCM. Wall Street Zen cut shares of HUTCHMED from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 22nd. HSBC downgraded shares of HUTCHMED from a "buy" rating to a "hold" rating in a report on Tuesday, May 13th.
Check Out Our Latest Research Report on HCM
HUTCHMED Profile
(
Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Featured Articles
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
